Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

Partner CStone Announces Positive NSCLC Results For Sugemalimab

Executive Summary

EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.

You may also be interested in...



Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors

China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.

Managing Lifecycles Amid Stifling Competition

Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel